The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases

Digestive Diseases

Volumn 30, Issue 3, 2012, Pages 289-295

  Lakatos, Gábor ^a,b   Hritz, István ^a,c   Varga, Mária Zsófia ^a   Juhász, Márk ^a   Miheller, Pál ^a   Cierny, Gabriel ^a   Tulassay, Zsolt ^a   Herszényi, László ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Szent Laszlo Hospital   (Hungary)

^c Szent Gyorgy Hospital   (Hungary)

Author keywords

Crohn's disease; Disease activity; Inflammation; Matrix metalloproteinase; Tissue inhibitor of matrix metalloproteinase; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; GELATINASE A; GELATINASE B; MATRILYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULCERATIVE COLITIS;

ADULT; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84862883383     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000336995     Document Type: Article

References (69)

1. Xavier RJ, Pdolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434. (Pubitemid 47123518)
2. Kucharzik T, Maaser C, Lugering A, et al: Recent understanding of IBD pathogenesis: Implications for future therapies. Inflamm Bowel Dis 2006; 12: 1068-1083.
3. Abraham C, Medzhitov R: Interactions between the host innate immune system and microbs in inflammatory bowel disease. Gastroenterology 2011; 140: 1729-1737.
4. Cho JH, Brant SR: Recent insights in the genetics of inflammatory bowel disease. Gastroenterology 2011; 140: 1704-1712.
5. Batra A, Stroh T, Siegmund B: Extraluminal factors contributing to inflammatory bowel disease. World J Gastroenterol 2011; 17: 572-577.
6. Herszényi L, Plebani M, Carraro P, et al: Proteases in gastrointestinal neoplastic disease. Clin Chimica Acta 2000; 291: 171-187.
7. Liotta LA, Stetler-Stevenson WG: Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res 1991; 51: 5054-5059.
8. Garg P, Ravi A, Patel NR, et al: Matrix metalloproteinase- 9 regulates MUC-2 expression through its effect on goblet cell differentiation. Gastroenterology 2007; 132: 1877-1889. (Pubitemid 46677943)
9. Rath T, Roderfeld M, Graf J, Roeb E: Matrix metalloproteinases in inflammatory bowel disease - from basic research to clinical significance. Z Gastroenterol 2009; 47: 758-769.
10. Hayden DM, Forsyth C, Keshavarzian A: The role of matrix metalloproteinases in intestinal epithelial wound healing during normal and inflammatory states. J Surg Res 2011; 168: 315-324.
11. Polgar L: Common feature of the four types of protease mechanisms. Biol Chem Hoppe- Seyler 1990; 371(suppl):327-331. (Pubitemid 20331121)
12. Plebani M, Herszényi L, Cardin R, et al: Cysteine and serine proteases in gastric cancer. Cancer 1995; 76: 367-375.
13. Herszényi L, Plebani M, Carraro P, et al: The role of cysteine and serine proteases in colorectal cancer. Cancer 1999; 86: 1135-1142. (Pubitemid 29446994)
14. Herszényi L, Farinati F, Cardin R, et al: Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-Type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 2008; 8: 194.
15. Herszényi L, Plebani M, Carraro P, et al: Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer. Am J Gastroenterol 1997; 92: 843-847. (Pubitemid 27200803)
16. Herszényi L, István G, Cardin R, et al: Serum cathepsin B and plasma urokinase-Type plasminogen activator levels in gastrointestinal tract cancers. Eur J Cancer Prev 2008; 17: 438-445.
17. Affara NI, Andreau P, Coussens LM: Delineating protease functions during cancer development. Methods Mol Biol 2009; 539: 1-32.
18. Gialeli C, Theocharis AD, Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278: 16-27.
19. Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: Regulators of the tumor miroenvironment. Cell 2010; 141: 52-67.
20. Page-McCaw A, Ewald AJ, Werb Z: Matrix metalloproteinases and the regulation of tissue remodeling. Nat Rev Mol Cell Biol 2007; 8: 221-233.
21. Puthenedam M, Wu F, Shety A, et al: Matrilysin (MMP7) cleaves gelactin-3 and inhibits wound healing in intestinal epithelial cells. Inflamm Bowel Dis 2011; 17: 260-267.
22. Monteleone G, Caruso R, Fina D, Peluso I, Gioia V, Stolfi C, Fantini MC, Caprioli F, Tersigni R, Alessandroni L, MacDonald TT, Pallone F: Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006; 55: 1774-1780. (Pubitemid 44893577)
23. Jensen SA, Vainer B, Bartels A, et al: Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells - associations with histopathology and patients outcome. Eur J Cancer 2010; 46: 3233-3242.
24. Kirkegaard T, Hansen A, Bruun E, Brynskov J: Expression and localization of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 2004; 53: 701-709. (Pubitemid 38561449)
25. Stallmach A, Chan CC, Ecker KW, Feifel G, Herbst H, Schuppan D, Zeitz M: Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut 2000; 47: 415-422.
26. Naito Y, Yoshikawa T: Role of matrix metalloproteinases in inflammatory bowel disease. Mol Aspects Med 2005; 26: 379-390. (Pubitemid 41225360)
27. Ravi A, Garg P, Sitaraman SV: Matrix metalloproteinases in inflammatory bowel disease: Boon or a baine? Inflamm Bowel Dis 2007; 13: 97-107. (Pubitemid 46080015)
28. Pender SL, Tickle SP, Docherty AJ, et al: A major role of matrix metalloproteinases in T cell injury in the gut. J Immunol 1997; 158: 1582-1590. (Pubitemid 127469511)
29. Castaneda FE, Walia B, Vijay-Kumar M, et al: Targeted deletion of metalloproteinase-9 attenuates experimental colitis in mice: Central role of epithelial-derived MMP. Gastroenterology 2005; 129: 1991-2008. (Pubitemid 41772976)
30. Esposito E, Mazzon E, Riccardi L, et al: Matrix metalloproteinase-9 and matrix metalloproteinase- 2 activity and expression is reduced by melatonin during experimental colitis. J Pineal Res 2008; 45: 166-173.
31. Garg P, Vijay-Kumar M, Wang L, et al: Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointest Liver Physiol 2009; 296:G175-G184.
32. Herszényi L, Hritz I, Pregun I, et al: Alterations of glutathione S-Transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. World J Gastroenterol 2007; 13: 676-682.
33. Herszényi L, Sipos F, Galamb O, et al: Matrix metalloproteinase-9 expression in the normal mucosa-Adenoma-dysplasia-Adenocarcinoma sequence of the colon. Pathol Oncol Res 2008; 14: 31-37.
34. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-1149. (Pubitemid 30123793)
35. Gao Q, Meijer MJ, Kubben FJ, et al: Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis 2005; 37: 584-592. (Pubitemid 44356072)
36. Lakatos G, Sipos F, Miheller P, et al: The behavior of matrix metalloproteinase-9 in lymphocytic colitis, collagenous colitis and ulcerative colitis. Pathol Oncol Res 2012; 18: 85-91.
37. Bailey CJ, Hembry RM, Alexander A, et al: Distribution of the matrix metalloproteinase stromelysin, gelatinase A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol 1994; 47: 113-116. (Pubitemid 24095461)
38. Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, Taylor CJ, Evans GS: Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999; 117: 814-822. (Pubitemid 29468223)
39. von Lampe B, Barthel B, Coupland SE, et al: Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000; 47: 63-73. (Pubitemid 30430413)
40. Meijer MJ, Mieremet-Ooms MA, van der Zon AM, et al: Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis 2007; 39: 733-739. (Pubitemid 47053808)
41. Jensen SA, Vainer B, Bartels A, et al: Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells - associations with histopathology and patients outcome. Eur J Cancer 2010; 46: 3233-3242.
42. Schrötzlmair F, Kopitz C, Halbgewachs B, et al: Tissue inhibitor of metalloproteinase-1- induced scattered liver metastasis is mediated by host-derived urokinase-Type plasminogen activator. J Cell Mol Med 2010; 14: 2760-2770.
43. Schelter F, Halbgewachs B, Bäumleer P, et al: Tissue inhibitor of metalloproteinase-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1 . Clin Exp Metastasis 2011; 28: 91-99.
44. Medina C, Radomski MW: Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 2006; 318: 933-938. (Pubitemid 44268297)
45. Wiercinska-Drapalo A, Jaroszewicz J, Flisiak R, Prokopowicz D: Plasma matrix metalloproteinase- 1 and tissue inhibitor of metalloproteinase- 1 as biomarkers of ulcerative colitis activity. World J Gastroenterol 2003; 9: 2843-2845. (Pubitemid 38054475)
46. Meijer MJ, Mieremet-Ooms MA, van Hogezand RA, et al: Role of matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase and tumor necrosis factor-Alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol 2007; 13: 2960-2966. (Pubitemid 47028884)
47. Meijer MJ, Mieremet-Ooms MA, van Hogezand RA, et al: Matrix metalloproteinases and their tissue inhibitors as prognostic indicators for diagnostic and surgical recurrence in Crohn's disease. Inflamm Bowel Dis 2009; 15: 84-92.
48. Kapsoritakis AN, Kapsoritaki AL, Davidi IP, et al: Imbalance of tissue inhibitors of metalloproteinases (TIMP) -1 and -4 serum levels in patients with inflammatory bowel disease. BMC Gastroenterol 2008; 8: 55.
49. Mäkitalo L, Kolho KL, Karikoski R, et al: Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease. Scan J Gastroenterol 2010; 45: 862-871.
50. Mary JY, Modigliani R: Development and validation of and endoscopic index of the severity for Crohn's disease: A prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30: 983-989.
51. Best WR, Becktel JM, Singleton JW, et al: Development of disease activity index. National cooperative Crohn's disease study. Gastroenterology 1976; 70: 439-444.
52. Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-Aminosalycilic acid therapy for mild to moderately active ulcerative colitis. N Engl J Med 1987; 317: 1625-1629. (Pubitemid 18010466)
53. D'Haens G, Sandborn WJ, Feagan BG, et al: A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-786.
54. Tarlton JF, Whiting CV, Tunmore D, et al: The role of up-regulated serine protease and matrix metalloproteinase in the pathogenesis of a murine model of colitis. Am J Pathol 2000; 157: 1927-1935.
55. Garg P, Jeppson S, Dalmasso G, et al: Notch1 regulates the effects of matrix metalloproteinase- 9 on colitis-Associated cancer in mice. Gastroenterology 2011;141:1381-1392.
56. Manfredi MA, Zurakowski D, Rufo PA, Walker TR, Fox VL, Moses MA: Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1091-1096.
57. Curran S, Dundas SR, Buxton J, et al: Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Cancer Res 2004; 10: 8229-8234. (Pubitemid 40053382)
58. Illemann M, Bird N, Majeed A, et al: MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res 2006; 4: 293-302. (Pubitemid 43837330)
59. Kirman I, Jain S, Cekic V, et al: Altered plasma matrix metalloproteinase-9/tissue inhibitor of matrix (corrected) metalloproteinase- 1 concentration during the early postoperative period in patients with colorectal cancer. Surg Endosc 2006; 20: 482-486. (Pubitemid 43260512)
60. Islekel H, Oktay G, Terzi C, et al: Matrix metalloproteinase- 9, -3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: Relationship to clinicopathological variables. Cell Biochem Funct 2007; 25: 433-441. (Pubitemid 47066721)
61. Sun J: Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells. J Signal Transduct 2010; 2010: 985132.
62. Gomez DE, Alonso DF, Yoshiji H, et al: Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122. (Pubitemid 27455388)
63. Lambert E, Dasse E, Haye B, Petitfrere E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004; 49: 187-198. (Pubitemid 38251351)
64. Kveiborg M, Jacobsen J, Lee MH, et al: Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2). Biochem J 2010; 430: 79-86.
65. Martinesi M, Treves C, Bonanomi AG, et al: Down-regulation of adhesion molecules and matrix metalloproteinases by ZK 156979 in inflammatory bowel diseases. Clin Immunol 2010; 136: 51-60.
66. Meijer MJ, Mieremet-Ooms MA, van Duijn W, et al: Effect of the tumor necrosis factoralpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 200-210. (Pubitemid 46806229)
67. Di Sabatino A, Pender SL, Jackson CL, et al: Functional modulation of Crohn's disease myofibroblasts by anti-Tumor necrosis factor antibodies. Gastroenterology 2007; 133: 137-149. (Pubitemid 47031137)
68. Kobayashi K, Arimura Y, Goto A, et al: Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphat sodium. J Pathol 2006; 209: 376-383. (Pubitemid 43997747)
69. Pedersen G, Saermark T, Kirkegaard T, Brynskov J: Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic mucosa. Clin Exp Immunol 2009; 155: 257-265.